An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2018
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 17 Jun 2018 Results of this and other study presented at the 23rd Congress of the European Haematology Association.
- 05 Jun 2018 Results from studies NCT01363297 and NCT01564784 presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 12 Dec 2017 Results from NCT01363297 and NCT01564784 studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History